{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-289865","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.403143+00:00","generated_at":"2026-05-16T17:57:10.761422+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025","bullets":["CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.","Separation benefits: 12 months base salary, 40% annual bonus, COBRA, full equity vesting.","Company has initiated search for new CFO; Neil F. McFarlane thanked Clifton for his leadership.","Clifton played role in company's transition from development to commercial-stage rare disease firm."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-289865","json":"https://secwatch.observer/filing/0001193125-25-289865.json","markdown":"https://secwatch.observer/filing/0001193125-25-289865.md","text":"https://secwatch.observer/filing/0001193125-25-289865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525289865/0001193125-25-289865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312525289865/d78999d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:57:10.761422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}